摘要
Nature Medicine 在线发表；doi:10.1038/s41591-026-04476-6。ADA 会议报告：230 名超重或肥胖成人中，aleniglipron 治疗 36 周较安慰剂最多减重 11.3%。
期刊：Nature Medicine；在线发表：2026年6月5日；doi:10.1038/s41591-026-04476-6
As presented at the American Diabetes Association Meeting: this randomized phase 2b trial in 230 adults with overweight or obesity shows that aleniglipron, an oral small-molecule GLP1-RA, led to up to 11.3% body-weight loss compared with placebo after 36 weeks of treatment.